DUBLIN – Themis Bioscience GmbH closed a €40 million (US$44.3 million) series D round that will enable it to complete an imminent phase III trial of a candidate vaccine for Chikungunya virus, MV-Chik, and to undertake its first clinical studies of its measles virus vector in oncology indications.